Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Part A:~* Overtly healthy males or females, as determined by medical history and physical examination~* Female participants not of child-bearing potential~Part B:~* Have a clinical diagnosis of idiopathic Parkinson's disease for at least 1 year and on stable medication for at least 4 weeks~Part A and B~* Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures~* Have given written informed consent~* Have a body mass index (BMI) of 18.0 to 29.9 kilograms per square meter (kg/m²)~Exclusion Criteria:~* Have participated, in the last 30 days, in a clinical trial involving an investigational product~* Have a significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders capable of significantly altering the absorption, metabolism or elimination of drugs; or constituting a risk when taking the study medication; or interfering with the interpretation of study data

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- LY3154207 (Type: EXPERIMENTAL): LY3154207 administered orally once daily in multiple-ascending dose cohorts for 14 days.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matching LY3154207 administered once daily for 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).